Compare COO & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COO | VTRS |
|---|---|---|
| Founded | 1980 | 1961 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.1B | 14.2B |
| IPO Year | N/A | N/A |
| Metric | COO | VTRS |
|---|---|---|
| Price | $84.34 | $12.44 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 11 | 6 |
| Target Price | ★ $88.55 | $11.50 |
| AVG Volume (30 Days) | 2.9M | ★ 8.4M |
| Earning Date | 12-04-2025 | 02-26-2026 |
| Dividend Yield | N/A | ★ 3.88% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.87 | N/A |
| Revenue | $4,092,400,000.00 | ★ $14,124,400,000.00 |
| Revenue This Year | $6.56 | N/A |
| Revenue Next Year | $5.32 | $1.18 |
| P/E Ratio | $44.25 | ★ N/A |
| Revenue Growth | ★ 5.06 | N/A |
| 52 Week Low | $61.78 | $6.85 |
| 52 Week High | $100.24 | $12.62 |
| Indicator | COO | VTRS |
|---|---|---|
| Relative Strength Index (RSI) | 66.90 | 71.74 |
| Support Level | $80.23 | $12.19 |
| Resistance Level | $83.64 | $12.62 |
| Average True Range (ATR) | 1.40 | 0.28 |
| MACD | -0.23 | 0.01 |
| Stochastic Oscillator | 97.88 | 79.28 |
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.